Objective: This study aimed to evaluate endothelial microparticles (EMPs) as a potential prognostic marker in hemolytic disease of the Chinese neonate.
Methods: We compared 29 newborns with ABO hemolytic disease of the newborn (ABO HDN), 22 newborns with Rh HDN, and 21 healthy newborns with matched mother and infant blood groups (controls). Markers of hemolysis and von Willebrand factor antigen (vWF Ag) were analyzed. EMP (CD144+) levels were measured before and after therapy.
Results: vWF Ag and pretherapy EMP levels were higher in the ABO HDN and Rh HDN groups than in the control group. Additionally, vWF Ag and pretherapy EMP levels were significantly higher in the ABO HDN group than in the Rh HDN group. Posttherapy EMP levels were decreased compared with pretherapy levels in the ABO HDN and Rh HDN groups. Moreover, hemoglobin and indirect bilirubin levels were independently correlated with pretherapy EMP levels in the ABO HDN group.
Conclusion: Our findings indicate that EMP measurement in neonates with HDN may provide a novel method of monitoring possible severe vascular dysfunction in patients in China. An external validation in larger datasets is necessary for further study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862913 | PMC |
| http://dx.doi.org/10.1177/0300060519870947 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics and Prognosis of Hemolytic Disease of the Newborn Caused by Irregular Antibodies: A 13-Year Retrospective Analysis.
Children (Basel)
November 2024
Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China.
Background/objectives: The clinical characteristics and outcomes of hemolytic disease of the newborn (HDN) caused by irregular antibodies remain unclear. Herein, we analyzed the clinical features and prognosis of HDN.
Methods: Children admitted to our institution between June 2009 and December 2022 with a definite diagnosis of HDN were evaluated.
A Comparative Analysis of the Efficacy of Blood Exchange Therapy in Neonatal Hyperbilirubinemia Induced by ABO and Rh Incompatibility.
Int J Gen Med
December 2024
Blood Transfusion Department, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Background: This study challenges the prevailing view that hemolytic diseases of the newborn (HDN) associated with the Rh blood group system are more severe than those caused by the ABO system. The objective was to assess the effectiveness of exchange transfusion (ET) in managing HDN, with a focus on comparing treatment outcomes between ABO and Rh incompatibility cases.
Methods: A study enrolled 125 neonates diagnosed with hyperbilirubinemia, comprising 66 males and 59 females.
Risk of low levels of blood group antibodies mediating hemolysis in ABO-incompatible neonates with negative three hemolysis tests.
Front Pediatr
August 2024
Department of Blood Transfusion, Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China.
Objective: To explore the risk of low-level blood group antibody-mediated hemolysis in ABO-incompatible newborns with negative three hemolysis tests, aiming to assist in the identification and management of neonatal jaundice.
Methods: A retrospective case-control study was performed in 892 children with jaundice. The patients were divided into three groups: group I, ABO compatible, negative three hemolysis tests; group II, ABO incompatible, negative three hemolysis tests; and group III, ABO incompatible, positive three hemolysis tests.
The Diagnostic Potential of the L Score for ABO Hemolytic Disease of the Newborn: Insights from a Cross-Sectional Study.
Indian J Hematol Blood Transfus
July 2024
Department of Clinical Laboratory, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410004 Hunan China.
Purpose: This study aimed to evaluate the diagnostic efficacy of the L score, a novel scoring system, in distinguishing between ABO hemolytic disease of the newborn (ABO-HDN) and non-hemolytic disease of newborn hyperbilirubinemia (NHDNH).
Methods: A cross-sectional prospective study was conducted to assess the effectiveness of the L score in distinguishing between ABO-HDN ( = 118) and NHDNH ( = 213). Blood routine examination results were collected, and relevant statistical analyses were performed to identify clinically significant parameters.
Effect of intravenous immunoglobulin on the management of Rh- and ABO-mediated hemolytic disease of the newborn.
Hematol Transfus Cell Ther
November 2024
Department of Immunology, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran. Electronic address:
Background: Regarding the close association between neonatal hyperbilirubinemia and occurrence of pathological jaundice as a cause of neurotoxicity and kernicterus, the present study aimed to evaluate the use of intravenous immunoglobulin (IVIG) in neonates with hyperbilirubinemia.
Methods: A retrospective case-control study of blood group O mothers and their ABO and Rh newborns was conducted. Medical records that included total serum bilirubin levels of 79 patients with hemolytic disease of the newborn (HDN) from between 2017 and 2020 were reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!